详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Denosumab for giant cell tumors of bone from 2010 to 2022: a bibliometric analysis

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Dermatology, Affiliated Hospital of Southwest Medical University, Luzhou, China. [2]Department of Orthopedic, Affiliated Hospital of Southwest Medical University, Luzhou, China. [3]Sichuan Provincial Laboratory of Orthopaedic Engineering, Luzhou, China. [4]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, China [5]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China [6]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, China [7]State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China

出处：

DOI：

ISSN：

关键词： Denosumab Giant cell tumor of bone Bibliometric analysis Hotspots Emerging trends

摘要：

Giant cell tumors of the bone (GCTB) are considered moderately malignant bone tumors. Denosumab, as a neoadjuvant therapy, provides new possibilities for treating GCTB. However, even after multiple studies and long-term clinical trials, there are limitations in the treatment process. Research data and Medical Subject Headings terms related to denosumab and GCTB were collected from January 2010 to October 2022 using the Web of Science and MeSH ( https://meshb.nlm.nih.gov ) browsers. These data were imported into CiteSpace and VOSviewer softwares for bibliometric analysis. Overall, 445 publications on denosumab and GCTB were identified. Over the last 12 years, the growth rate of the total number of publications has remained relatively stable. The USA published the highest number of articles (83) and had the highest centrality (0.42). Amgen Inc. and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) First Ortoped Rizzoli were identified as the most influential institutions. Many authors have made outstanding contributions to this field. Lancet Oncology had the highest journal impact factor (54.433). Local recurrence and drug dosage are current research hotspots, and future development trends will mainly focus on prognostic markers of GCTB and the development of new therapies. Further research is required to analyze denosumab's safety and efficacy and understand its local recurrence of GCTB, to identify the optimal dose. Future progress in this field will likely focus on exploring new diagnostic and recurrence markers to monitor disease progression and examine new therapeutic targets and treatment strategies.© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

最新[2023]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Dermatology, Affiliated Hospital of Southwest Medical University, Luzhou, China.

共同第一作者：

通讯作者：

通讯机构： [2]Department of Orthopedic, Affiliated Hospital of Southwest Medical University, Luzhou, China. [3]Sichuan Provincial Laboratory of Orthopaedic Engineering, Luzhou, China. [4]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, China [5]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China [6]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, China [7]State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Denosumab for giant cell tumors of bone from 2010 to 2022: a bibliometric analysis

文献详情

相关文献